A growing body of evidence indicates that some novel tubular biomarkers have excellent predictability for chronic kidney disease (CKD) or acute kidney injury (AKI), and may exhibit a promising perspective on the early diagnosis for DKD, such as neutrophil gelatinase-associated lipocalin (NGAL), cystatin C (CysC), and clusterin (CLU) [12–16]. Here, CLU is linked to diabetic kidney disease.